{"nct_id":"NCT06564844","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"RECRUITING","status_verified_date":"2025-08","start_date":"2024-10-15","start_date_type":"ACTUAL","primary_completion_date":"2033-05-19","primary_completion_date_type":"ESTIMATED","completion_date":"2035-01-19","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}